Understand the source comparison
The Blunt Truth About Spadin vs PE-22-28 Confusion
Here's the honest answer: the peptide research market uses 'Spadin analog' as shorthand for anything structurally related to Spadin, and this creates procurement chaos. PE-22-28 is not 'a Spadin analog' in the way acetylated Spadin or D-amino-acid Spadin are a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Here's the honest answer: the peptide research market uses 'Spadin analog' as shorthand for anything structurally related to Spadin, and this creates procurement chaos. PE-22-28 is not 'a Spadin analog' in the way acetylated Spadin or D-amino-acid Spadin are analogs. It's a completely different peptide derived from the same parent sequence. The molecular weight is half the size. The IC50 is three times higher. The stability profile is categorically different. Calling it a Spadin analog is technically accurate in the broadest sense, but practically misleading.
- We've reviewed purchasing records from research labs that ordered 'Spadin analog,' received PE-22-28, and only discovered the substitution when results didn't replicate. This isn't supplier fraud. It's nomenclature ambiguity that buyers and sellers have failed to standardise. If your experimental design depends on specific pharmacological properties (potency, half-life, receptor selectivity), you must specify the exact structure you need: full-length Spadin, PE-22-28, or a named modification (acetylated, methylated, D-amino-acid substituted). Certificate of analysis (CoA) documents should include HPLC chromatograms and mass spectrometry data confirming molecular weight. If your supplier can't provide these, you're buying on faith.
- The cost difference compounds the problem. PE-22-28 synthesis is 40–60% cheaper than full-length Spadin due to shorter chain length and simpler purification. Some suppliers substitute PE-22-28 for Spadin orders to improve margins, betting that most buyers won't run confirmatory analytics. The solution is pedantic specificity: write 'full-length Spadin (17 amino acids, MW ~1,800 Da)' or 'PE-22-28 fragment (residues 22–28, MW ~800 Da)' in your purchase orders and methods sections. Ambiguity serves no one except suppliers willing to exploit it.
- For high-stakes research requiring reproducibility across sites or publications, our peptide synthesis standards include batch-specific analytical documentation and sequence confirmation for every order. Spadin analog and PE-22-28 are catalogued as distinct products with separate SKUs, eliminating substitution risk. The cost of confirmatory analytics is negligible compared to the cost of a failed replication study or retracted publication.
- The question 'is Spadin analog same as PE-22-28' reflects a deeper problem in peptide research procurement: suppliers and researchers using different definitions for the same term. PE-22-28 is a Spadin-derived fragment, not a structural analog in the sense of modified full-length Spadin. The distinction is not semantic. It determines experimental outcomes, dosing protocols, and data interpretation. If your research depends on TREK-1 channel inhibition, specify which compound you need by structure, not by category label, and demand analytical proof of identity before running experiments.